MajorTricyclic antidepressants (TCA)×Central α2-adrenergic agonist
Updated · Methodology
Mechanism
Tricyclic antidepressants, amitriptyline included, can counteract centrally acting antihypertensives such as clonidine (amitriptyline SmPC). The clonidine SmPC adds that the blood pressure lowering effect of clonidine may be reduced or lost entirely. The combination can also cause or worsen orthostatic dysregulation, a drop in blood pressure on standing (clonidine SmPC).
Symptoms
Blood pressure drifts above target: home and clinic readings are higher than before, and some patients get headache or dizziness. On standing, orthostatic hypotension can cause dizziness and weakness (clonidine labels).
Management
The combination is not recommended: the Spanish amitriptyline SmPC lists clonidine under combinations that are not recommended and advises reviewing all antihypertensive treatment while a tricyclic antidepressant is used. When reviewing it, keep in mind that clonidine may stop lowering blood pressure and that orthostatic dysregulation may get worse (clonidine SmPC). The FDA clonidine label notes that a higher clonidine dose may be needed with tricyclic antidepressants. If clonidine is to be stopped, do not stop it abruptly: taper the dose over 2–4 days, otherwise blood pressure can rise quickly. In a patient also taking a beta-blocker, withdraw the beta-blocker gradually first and clonidine after it (clonidine SmPC).
Check the full regimen, not just this pair
Opens the checker with these two drugs prefilled. Add the rest of the regimen and recompute additive risks.
Summary of a multi-drug list →
Medicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Amitriptilina (nº registro 89862), sección 4.5 (2026)– AEMPS, CIMA, nº registro 89862, revisión 05/2026, sección 4.5
- AEMPS: Ficha técnica: Amitriptilina (nº registro 37130), secciones 4.4 y 4.5 (2025)– AEMPS, CIMA, nº registro 37130, revisión 01/2025, secciones 4.2, 4.3, 4.4, 4.5 y 4.9
- AEMPS: Ficha técnica: Clonidina (nº registro 50669), sección 4.5 (2023)– AEMPS, CIMA, nº registro 50669, revisión 05/2023, secciones 4.4 y 4.5
- FDA: Catapres-TTS (clonidine) prescribing information (2026)– FDA label, Technomed Inc., DailyMed setid 39e1d35e-533c-4647-8649-8168a6e92dfa, revised 01/2026, Precautions (Drug Interactions)